Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
暂无分享,去创建一个
M. Mack | P. Kufer | G. Riethmüller | R. Lutterbüse | R. Gruber | F. Zettl | Gert Riethmüller | Matthias Mack | Rudolf Gruber
[1] M. Mack,et al. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. , 1997, Journal of immunology.
[2] M. Mack,et al. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] L. de Leij,et al. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. , 1994, British journal of cancer.
[4] P. D. De Mulder,et al. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2. , 1993, Journal of the National Cancer Institute.
[5] T. Yokota,et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.
[6] G. Riethmüller,et al. The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.
[7] J. Bluestone,et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.
[8] Osami Kanagawa,et al. Hybrid antibodies can target sites for attack by T cells , 1985, Nature.
[9] H. Koprowski,et al. Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody , 1984, International journal of cancer.